Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape

June 27, 2024

https://www.globenewswire.com/news-release/2024/06/27/2905033/0/en/Cellectar-Biosciences-to-Host-Key-Opinion-Leader-Event-to-Review-the-Full-Results-from-Its-CLOVER-WaM-Pivotal-Trial-and-Waldenstrom-s-Macroglobulinemia-Market-Landscape.html

FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 2024, at 8:00 a.m., EDT, to provide a comprehensive overview of recent data from its pivotal trial of iopofosine I 131 in Waldenstrom’s macroglobulinemia, the current treatment landscape, unmet needs for patients with this disease, and opportunities to improve patient outcomes.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.